Citations

Clear

815 citation(s) found for "Tang, Yu".

Time Course scRNAseq Analysis Reveals Mechanisms of Impaired Lung Recovery Post Influenza Infection during Aging: Zooming into Macrophages
Wu, Yue , Gao, Xiaochen , Li, Ying , Fain, Cori E. , Johnson, Aaron J. , Tang, Jinyi , Li, Chaofan , Zhu, Bibo , Santos, Gislane de Almeida , Narasimhan, Harish , Zhang, Ruixuan , Ayasoufi, Katayoun , Johnson, Aaron J. , Dong, Haidong , Sun, Jie

Mayo Clinic

The Journal of Immunology | August 10, 2023 | Volume: 210 | Issue: Supplement_1 | Pages: 71.24-71.24

10.4049/jimmunol.210.supp.71.24 Get It

Abstract Aging is considered to be a major risk factor for host morbidity and mortality upon acute respiratory virus infections. To better elucidate the immune determinants of viral pathogenesis during aging, we chronological characterized lung cellular and molecular profiles following influenza virus (PR8) infection in young or aged mice till 60 days post infection. Time-course scRNAseq coupled with high dimensional flow cytometry enabled the description of changes in both immune and stromal compartment between young and aged hosts. We further zoomed into the myeloid compartment and focused on the dynamic responses of lung macrophages given their complex roles in viral pathogenesis, tissue repair and lung fibrosis. Enlarged Monocyte-derived Macrophage (MoM) population as well as decreased resident-Alveolar Macrophage (AM) population were observed in the aged mice when compared to those of the young mice. Despite the self-sustain nature of AMs during homeostasis, it has been reported that Ly6Chi monocytes can gain AM identity following severe lung damage like influenza virus infection. We found that the gain of AM identity from monocytes was abrogated in the aged hosts, which likely contributed to the age-associated impairment in lung recovery after influenzas virus infection. Additionally, trajectory analysis with scRNAseq allowed us to identify IFNα/γ signaling to be potential pathways contributing to such defect. This notion is also supported by elevated IFNγ level in BAL from the aged host during lung recovery. Our results thus have improved our understanding on the cellular and molecular mechanisms by which aged hosts exhibit severe diseases and delayed recovery after respiratory viral infection.
P915: TREATMENT PATTERNS AND CLINICAL OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY TREATED WITH LENALIDOMIDE AND AN ANTI-CD38 MONOCLONAL ANTIBODY: FINDINGS FROM THE CONNECT MM DISEASE REGISTRY
Abonour, Rafat , Rifkin, Robert M. , Gasparetto, Christina, Durie, Brian G.M. , Terebelo, Howard R. , Narang, Mohit , Toomey, Kathleen, Tang, Yuexin , Dhanasiri, Sujith, Anand, Jasmeet, Yu, Edward, Marshall, Thomas, Liu, Liang , Ailawadhi, Sikander , Lee, Hans C. , Wagner, Lynne I. , Hardin, James W. , Jagannath, Sundar

Mayo Clinic

HemaSphere | August 9, 2023 | Volume: 7 | Issue: S3 | Pages: e52503e2

10.1097/01.hs9.0000970564.52503.e2 Get It

P1215: CHARACTERIZATION AND CLINICAL SIGNIFICANCE OF T FOLLICULAR HELPER SUBSETS IN FOLLICULAR LYMPHOMA
Tang, Xinyi , Mukherjee, Prithviraj , Novak, Anne J. , Ansell, Stephen M. , Yang, Zhi-Zhang , Kim, Hyo Jin , Bhardwaj, Vaishali , Mondello, Patrizia , Villasboas, José C.

Mayo Clinic

HemaSphere | August 9, 2023 | Volume: 7 | Issue: S3 | Pages: e5464225

10.1097/01.hs9.0000971756.54642.25 Get It

SDPS-31 EXTRACELLULAR VESICLES AND THEIR CARGO AS A PHARMACODYNAMIC REPORTER IN GLIOBLASTOMA
DeLuca, Valerie , Tang, Nanyun , Hao, Yue , Raju, Anjali, Shaffer, Charles, Riviere-Cazaux, Cécile , Pirrotte, Patrick , Keuren‐Jensen, Kendall Van , Burns, Terry C. , Sarkaria, Jann N. , Parney, Ian F. , Berens, Michael E.

Mayo Clinic

Neuro-Oncology Advances | August 4, 2023 | Volume: 5 | Issue: Supplement_3 | Pages: iii22-iii22

10.1093/noajnl/vdad070.086 Get It

Abstract Glioblastoma (GBM) is a lethal brain tumor with limited treatment options, due in part to the low blood-brain-barrier (BBB) penetrance of many anti-cancer compounds. Development of a non-invasive test that can measure drug delivery and target engagement in GBM represents an opportunity to enhance knowledge during early phase clinical trials of a new compound’s pharmacological suitability and potential efficacy. We present here data supporting that the cargo within extracellular vesicles (EV) can potentially serve as a liquid biopsy that reports on the pharmacodynamics of GBM therapeutics. We treated short-term cell cultures established from four patient-derived xenografts with vehicle, temozolomide, MLN4924, or arsenic trioxide. EVs were isolated from culture supernatants using size exclusion chromatography and then analyzed by RNA sequencing and mass spectrometry (proteomics) to characterize and compare cargo profiles for each condition. We found that depending on treatment, there were shared alterations in EV cargo between models in the expression of long non-coding RNAs, genes that are overrepresented in biological processes such as cytoplasmic translation and cellular macromolecule biosynthesis, and circular RNAs. Mass spectrometry of protein cargo further demonstrated both upregulated and downregulated peptide abundances with treatment compared to vehicle. Thus, our preliminary results indicate that EV cargo post-treatment may be a novel pharmacodynamic reporter in GBM. To allow for the selective interrogation of patient GBM-derived EVs, we have simultaneously pursued the identification of biomarkers to allow for immunoprecipitation of EVs from patient biofluids. Potential biomarkers, including PTPRZ1, B7H3, and IL13RA2, were screened across isolated EVs from both pre-clinical and clinical patient samples. Future efforts are focused on evaluating immunoprecipitated GBM-EVs from longitudinally collected patient biofluids. Overall, we anticipate that the results of this study will lead to development of a clinical test that reflects BBB penetration and tumor response, which will likely aid in novel drug development efforts.
Common Variants on FGD5 Increase Hazard of Mortality or Rehospitalization in Patients With Heart Failure From the ASCEND-HF Trial
Gui, Hongsheng , Tang, W.H. Wilson , Francke, Stephan, Li, Jia , She, Ruicong , Bazeley, Peter , Pereira, Naveen L. , Adams, Kirkwood F., Williams, L. Keoki , Luzum, Jasmine A , Hernandez, Adrian , McNaughton, Candace D , Williams, L Keoki , Lanfear, David E , Tang, W H Wilson , Luzum, Jasmine A. , Connolly, Thomas M., Hernandez, Adrian F.

Mayo Clinic

Circulation: Heart Failure | July 26, 2023 | Volume: 16 | Issue: 9 | Pages: No page available

10.1161/circheartfailure.122.010438 | PMID 37725680 Get It

BACKGROUND: Heart failure remains a global health burden, and patients hospitalized are particularly at risk, but genetic associates for subsequent death or rehospitalization are still lacking. METHODS: The genetic substudy of the ASCEND-HF trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) was used to perform genome-wide association study and transethnic meta-analysis. The overall trial included the patients of self-reported European ancestry (n=2173) and African ancestry (n=507). The end point was death or heart failure rehospitalization within 180 days. Cox models adjusted for 11 a priori predictors of rehospitalization and 5 genetic principal components were used to test the association between single-nucleotide polymorphisms and outcome. Summary statistics from the 2 populations were combined via meta-analysis with the significance threshold considered P <5×10 − 8 . RESULTS: Common variants (rs2342882 and rs35850039 in complete linkage disequilibrium) located in FGD5 were significantly associated with the primary outcome in both ancestry groups (European Americans: hazard ratio [HR], 1.38; P =2.42×10 −6 ; African ancestry: HR, 1.51; P =4.43×10 − 3 ; HR in meta-analysis, 1.41; P =4.25×10 −8 ). FGD5 encodes a regulator of VEGF (vascular endothelial growth factor)-mediated angiogenesis, and in silico investigation revealed several previous genome-wide association study hits in this gene, among which rs748431 was associated with our outcome (HR, 1.20; meta P <0.01). Sensitivity analysis proved FGD5 common variants survival association did not appear to operate via coronary artery disease or nesiritide treatment ( P >0.05); and the signal was still significant when changing the censoring time from 180 to 30 days (HR, 1.39; P =1.59×10 −5 ). CONCLUSIONS: In this multiethnic genome-wide association study of ASCEND-HF, single-nucleotide polymorphisms in FGD5 were associated with increased risk of death or rehospitalization. Additional investigation is required to examine biological mechanisms and whether FGD5 could be a therapeutic target. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT00475852.
SPONTANEOUS IMPROVEMENT OF MYOPIC RETINOSCHISIS AFTER A LONG-TERM OBSERVATIONAL PERIOD: A CASE SERIES
Hussein, Musse, Adeleye, Olufunmilola , Adams, Olufemi E. , Sodhi, Guneet S., Haq, Zeeshan , Quiram, Polly A., Tang, Peter H. , Ryan, Edwin H. , Adeleye, Olufunmilola

Mayo Clinic

RETINAL Cases & Brief Reports | July 18, 2023 | Volume: 18 | Issue: 5 | Pages: 553-561

10.1097/icb.0000000000001453 | PMID 37463473 Get It

Purpose: To highlight spontaneous resolution or improvement of myopic retinoschisis (MR) in actively surveilled patients. Methods: Case series of five patients diagnosed with MR who did not undergo pars plana vitrectomy and were carefully monitored by a single retina specialist. Ocular and medical history were reviewed, and clinical characteristics including visual acuity and the status of the MR were monitored with spectral domain optical coherence tomography (SD-OCT) at each clinic visit. Results: Five patients were identified to have MR without vitreomacular traction, or macular hole formation. Two patients exhibited spontaneous and complete resolution of MR without surgical intervention over an average observation time of 52.5 months. In these cases, a clinical posterior vitreous detachment was documented preceding the resolution of MR over an average time of 26.5 months. Snellen best-corrected visual acuity in these patients improved (Case 1 from 20/50 to 20/40, Case 2 from 20/30 to 20/25). The remaining three patients were monitored for an average of 52 months and showed improvement of MR via OCT imaging. Snellen best-corrected visual acuity either remained stable or improved from baseline (Case 3 stable at 20/30, Case 4 improved from 20/40 to 20/30, and Case 5 stable at 20/20). Conclusion: These findings suggest that conservative management of MR with observation can be considered especially in patients with challenging comorbidities (such as monocular status), and with a clinically identified posterior vitreous detachment without vitreomacular traction.
Fusion of imaging and non-imaging data for disease trajectory prediction for coronavirus disease 2019 patients
Tariq, Amara , Sakhi, Hifza, Newsome, Janice , Trivedi, Hari , Banerjee, Imon , Sakhi, Hifza , Rubin, Daniel L , Trivedi, Hari , Gichoya, Judy W. , Banerjee, Imon , Tang, Siyi , Celi, Leo Anthony , Rubin, Daniel L. , Gichoya, Judy Wawira

Mayo Clinic

Journal of Medical Imaging | June 28, 2023 | Volume: 10 | Issue: 03 | Pages: No page available

10.1117/1.jmi.10.3.034004 | PMID 37388280 Get It

Association of Statin Use With Risk of Liver Disease, Hepatocellular Carcinoma, and Liver-Related Mortality
Vell, Mara Sophie , Wangensteen, Kirk J. , Trebicka, Jonel , Creasy, Kate Townsend , Trautwein, Christian , Seeling, Katharina Sophie , Hehl, Leonida, Rendel, Miriam Daphne , Zandvakili, Inuk , Li, Tang , Alqahtani, Saleh A. , Schneider, Kai Markus , Schneider, Carolin V. , Trebicka, Jonel , Wangensteen, Kirk J , Scheider, Carolin , Loomba, Rohit , Krishnan, Arunkumar , Scorletti, Eleonora , Chen, Jinbo , Vujković, Marijana , Rader, Daniel J

Mayo Clinic

JAMA Network Open | June 26, 2023 | Volume: 6 | Issue: 6 | Pages: e2320222

10.1001/jamanetworkopen.2023.20222 | PMID 37358849 Get It

Importance Given the burden of chronic liver disease on the health care system, more information on the hepatoprotective association of statins in the general population is needed. Objective To examine whether regular statin use is associated with a reduction in liver disease, particularly hepatocellular carcinoma (HCC) and liver-related deaths, in the general population. Design, Setting, and Participants This cohort study used data from the UK Biobank (UKB) (individuals aged 37-73 years) collected from baseline (2006-2010) to the end of follow-up in May 2021, from the TriNetX cohort (individuals aged 18-90 years) enrolled from baseline (2011-2020) until end of follow-up in September 2022, and from the Penn Medicine Biobank (PMBB) (individuals aged 18-102 years) with ongoing enrollment starting in 2013 to the end of follow-up in December 2020. Individuals were matched using propensity score matching according to the following criteria: age, sex, body mass index, ethnicity, diabetes with or without insulin or biguanide use, hypertension, ischemic heart disease, dyslipidemia, aspirin use, and number of medications taken (UKB only). Data analysis was performed from April 2021 to April 2023. Exposure Regular statin use. Main Outcomes and Measures Primary outcomes were liver disease and HCC development as well as liver-associated death. Results A total of 1 785 491 individuals were evaluated after matching (aged 55 to 61 years on average, up to 56% men, and up to 49% women). A total of 581 cases of liver-associated death, 472 cases of incident HCC, and 98 497 new liver diseases were registered during the follow-up period. Individuals were aged 55-61 years on average, with a slightly higher proportion of men (up to 56%). In UKB individuals (n = 205 057) without previously diagnosed liver disease, statin users (n = 56 109) had a 15% lower hazard ratio (HR) for the association of developing a new liver disease (HR, 0.85; 95% CI, 0.78-0.92; P &amp;lt; .001). In addition, statin users demonstrated a 28% lower HR for the association with liver-related death (HR, 0.72; 95% CI, 0.59-0.88; P = .001) and a 42% lower HR for the development of HCC (HR, 0.58; 95% CI, 0.35-0.96; P = .04). In TriNetX individuals (n = 1 568 794), the HR for the association of HCC was reduced even further for statin users (HR, 0.26; 95% CI, 0.22-0.31; P = .003). The hepatoprotective association of statins was time and dose dependent, with a significant association in PMBB individuals (n = 11 640) for incident liver diseases after 1 year of statin use (HR, 0.76; 95% CI, 0.59-0.98; P = .03). Taking statins was particularly beneficial in men, individuals with diabetes, and individuals with a high Fibrosis-4 index at baseline. Carriers of the heterozygous minor allele of PNPLA3 rs738409 benefited from statin use and had a 69% lower HR for the association with HCC (UKB HR, 0.31; 95% CI, 0.11-0.85; P = .02). Conclusions and Relevance This cohort study indicates substantial preventive associations of statins against liver disease, with an association with duration and dose of intake.
Abstract 2310: Tumor macrophage fusion cells detected in the circulation of metastatic breast cancer patients is prognostic for rapid progression and death
Alpaugh, R. Katherine , Lapidus, Rena G. , Chumsri, Saranya , Gardner, Kirby P. , Tang, Cha‐Mei , Priore, Giuseppe Del, Adams, Daniel L. , Reduzzi, Carolina , Williams, William V. , Cristofanilli, Massimo

Mayo Clinic

Cancer Research | June 9, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 2310-2310

10.1158/1538-7445.am2023-2310 Get It

Abstract Background: Recently, it was described that macrophages and tumor cells can fuse to form tumor macrophage fusion cells (TMFs) which are detectable within primary tumors and patient’s (pts) circulation. However, there are multiple pathways and subsequent subtypes of TMFs, with limited data on the various TMF types, commonality in blood, and clinical relevance. Here we evaluated n=120 metastatic breast cancer (mBC) blood samples for CTCs & TMFs. We describe numerous types of TMFs with vastly different fusion phenotypes, including partial (i.e. some membrane interaction & both cells retaining their original phenotypes), homodimeric (i.e. both cells with fused membranes & sharing cytoplasm), cannibalistic (i.e. CTC within a CD14+ macrophage & cells retaining their individual phenotypes), binucleated (i.e. both cells completely merge & becoming one cell with dual expression phenotypes), and hyperploidy (i.e. multiple cells merge to form a large polyploid cell). As CTCs & TMFs are isolated in conjunction from a single blood sample, we evaluated both CTCs & all TMF subtypes to determine their prognostic and predictive values for aggressiveness of disease. Methods: We categorized and enumerated the 5 forms of TMFs from a prospective pilot study using n=120 mBC pts that were starting new lines of treatment. Whole peripheral blood (7.5mL) was procured, filtered and stained using cytokeratin & CD45/CD14 to identify CTCs & TMFs. We compared the presence of the various types of TMFs & CTCs to pt’s progression-free survival (PFS) and overall survival (OS) hazard ratios (HRs), analyzed by censored univariate analysis based on RECIST v1.1 over 24 months. Results: CTCs were found in 39% (n=47/120), with partial fusion TMFs in 26% (n=31/120), homodimeric 2% (n=2/120), cannibalistic 0% (n=0/120), binucleated 2% (n=2/120), hyperploidy 93% (n=113/120). Presence of CTCs alone, binucleated, or hyperploidy TMFs were not prognostic for PFS (p=0.0988, p=0.4120, & p=0.7615 respectively), or OS (p=0.2015, p=0.0845, p=0.1121 respectively). However, TMFs with partial or homodimeric fusion were prognostic for worse PFS (HR=2.2, p=0.0063 and HR=6.0, p=0.0305, respectively) and for worse OS (HR=2.8, p=0.0037 and HR=8.8, p=0.0271, respectively). Furthermore, combining pts with any TMFs into one group, minus hyperploidy, was highly significant for worse PFS (HR=2.9, 95%CI 1.7-5.0, p=0.0002) and worse OS (HR=3.8, 95%CI 2.0-7.5, p=0.0002), though certain subtypes of hyperploidy were also indicative of worse outcomes. Conclusion: The study of TMFs is relativity limited and their existence is new in oncology. Here we detected and described TMFs in the blood of mBC pts while demonstrating an association with poor clinical outcomes. These data suggest TMF involvement in the pathogenic cascade of cancer and further understanding of their biology may be important in the study of tumorigenesis. Citation Format: Daniel L. Adams, R. Katherine Alpaugh, Rena G. Lapidus, Saranya Chumsri, Carolina Reduzzi, Kirby P. Gardner, Cha-Mei Tang, Giuseppe Del Priore, William V. Williams, Massimo Cristofanilli. Tumor macrophage fusion cells detected in the circulation of metastatic breast cancer patients is prognostic for rapid progression and death [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2310.